Skip to main content

Normal Pressure Hydrocephalus

1
Pipeline Programs
6
Companies
6
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

6 companies ranked by most advanced pipeline stage

NeuroDx Development
1 program
1
Shunt flow detectionPhase 41 trial
Active Trials
NCT00793416Withdrawn0Est. Aug 2012
GE HealthCare
2 programs
[18F] FlutemetamolPHASE_31 trial
[18F]FlutemetamolPHASE_31 trial
Active Trials
NCT01053312Completed7Est. Aug 2010
NCT01092546Terminated12Est. Apr 2011
CereVasc
CereVascMA - Charlestown
1 program
CereVasc eShunt SystemN/A1 trial
Active Trials
NCT06498960Recruiting230Est. Jun 2031
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
1 program
Ventriculo-peritonal shuntingN/A1 trial
Active Trials
NCT00149721Terminated30Est. Dec 2007
Prevail Therapeutics
1 program
Ventriculo-peritonal shuntingN/A
UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
ventriculo-peritoneal shuntingN/A1 trial
Active Trials
NCT03092804Unknown60Est. Aug 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
NeuroDx DevelopmentShunt flow detection
GE HealthCare[18F]Flutemetamol
GE HealthCare[18F] Flutemetamol
CereVascCereVasc eShunt System
UNION therapeuticsventriculo-peritoneal shunting
Eli Lilly and CompanyVentriculo-peritonal shunting

Clinical Trials (6)

Total enrollment: 339 patients across 6 trials

NCT00793416NeuroDx DevelopmentShunt flow detection

ShuntCheck Accuracy in Detecting Shunt Obstruction Normal Pressure Hydrocephalus (NPH) Patients

Start: Nov 2008Est. completion: Aug 20120
Phase 4Withdrawn
NCT01092546GE HealthCare[18F]Flutemetamol

Positron Emission Tomography Imaging of Brain Amyloid in Normal Pressure Hydrocephalus

Start: Mar 2010Est. completion: Apr 201112 patients
Phase 3Terminated
NCT01053312GE HealthCare[18F] Flutemetamol

PET Imaging of Brain Amyloid in Normal Pressure Hydrocephalus

Start: Dec 2009Est. completion: Aug 20107 patients
Phase 3Completed
NCT06498960CereVascCereVasc eShunt System

Evaluation of the Safety and Effectiveness of the CereVasc® eShunt® System in Normal Pressure Hydrocephalus

Start: Nov 2024Est. completion: Jun 2031230 patients
N/ARecruiting
NCT03092804UNION therapeuticsventriculo-peritoneal shunting

The Brain Structure and Neural Network Changing the Before and After Ventriculo-peritoneal Shunting in the Normal Pressure Hydrocephalus Patients

Start: Aug 2016Est. completion: Aug 201960 patients
N/AUnknown
NCT00149721Eli Lilly and CompanyVentriculo-peritonal shunting

Anterior Pituitary Function in Patients With Hydrocephalus

Start: Sep 2005Est. completion: Dec 200730 patients
N/ATerminated

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 339 patients
6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.